Astellas Pharma (China) Co., Ltd (hereinafter referred to as "Astellas China") was established in August 2005 by changing the name of the former "Yamanouchi Pharmaceutical (China) Co. "On April 1, 2007, the company merged with Fujisawa Pharmaceuticals (China) Co. Both companies have been in China for more than 12 years and have established a good reputation. The merger enabled us to complement our major product lines, expand our product portfolio and focus our resources on the research and development of quality medicines. Astellas China is committed to continuing to meet the needs of its customers and to conduct its business activities in a highly ethical and moral manner. We will utilize our creativity under the mission of enhancing corporate value. We will realize sustainable business development and strive to become a company in China that is trusted by our customers, employees, government, related companies, social organizations and other stakeholders.
(Beijing, April 13, 2007) Astellas Pharma (China) Ltd. today officially announced the merger of Fujisawa Pharmaceuticals (China) Co. This merger marks the completion of the Astellas Pharma Group's final global merger in China.
Astellas, with global net sales of 880 billion yen (approximately 57.8 billion yuan) in fiscal 2005 (year-end in March 2006), is the second largest prescription drug company in Japan and the 18th largest pharmaceutical group in the world. Prior to the merger, both companies had more than 12 years of factory history and good reputation in China. The merged company will rapidly build up its business system in targeted therapeutic areas and strengthen its global competitiveness in the future to become a leading pharmaceutical company in the field of global therapeutic diseases.
The merger will allow the two companies to complement each other's major product lines, expand their product offerings, and focus on the development of superior medicines. Mr. Hidekazu Yokote, General Manager of Astellas China, said that Astellas China's main business activities are the manufacturing, sales and development of pharmaceutical products. The main products include immunosuppressant Proclofenac for the prevention and treatment of organ transplantation, prostate hyperplasia treatment drug HALO, peptic ulcer treatment drug GOSUDA, atopic dermatitis treatment drug PROTEPI, anti-fungal infections drug MICHELMIN, high blood pressure drug PELL and other medicines. amp;reg; and Nesia® for the treatment of nausea and vomiting induced by anti-malignant tumor therapies, etc.*** Eleven different varieties of products are available, and it is planned to achieve sales of approximately $600 million in fiscal year 2007.
The merger is expected to be completed by the end of the fiscal year.
The merged Astellas China employs approximately 490 people at its Shenyang manufacturing plant and at branch offices and liaison offices in major cities in China. In addition to continuing to optimize the advanced production technology at the Shenyang formulation plant, improve the domestic sales network, and enhance the professionalism of its personnel, Astellas China will expand its collaboration with Chinese research institutes through a co-development system. Astellas China is one of the largest pharmaceutical companies invested by Japan in China, and is a wholly owned subsidiary of Astellas Pharma Group in China. The plant is located in Shenyang Economic Development Zone, headquartered in Beijing, with branch offices in Shanghai, Beijing, Guangzhou, Chengdu and Shenyang, and operations in large and medium-sized cities throughout China, with about 500 employees nationwide.
Astellas China currently markets and sells products in China in a wide range of specialty areas including organ transplantation, urology, infection, skin, digestive cycle, etc., of which the products in the fields of transplantation and urology have already been recognized by the majority of doctors and patients, and are in a leading position in the market. In April 2005, the Astellas Pharma Group was established as a result of the business integration of Yamanouchi Pharmaceutical Company Limited and Fujisawa Pharmaceutical Industry Co.
Anstellas Pharma Group is a research and development pharmaceutical company headquartered in Tokyo, Japan, the second largest prescription pharmaceutical company in Japan and the 18th largest pharmaceutical group in the world. We develop, manufacture and market innovative pharmaceutical products globally. We are committed to contributing to the health of people all over the world through innovative and reliable pharmaceutical products, realizing the significance of our existence, and our mission is to continuously enhance corporate value.
We have identified a competitive business model in the face of global competition, taking into account the external market environment, the company's existing strengths and its potential for future development - that is, to become a "global leader in specialized therapeutic areas" in six key therapeutic areas. The company's business model is to become a "global leader in specialized therapeutics" in six key therapeutic areas. Japanese pharmaceutical companies, which have always kept a low profile, have begun to make frequent appearances and make efforts in the Chinese pharmaceutical market. A few days ago, Japan's largest pharmaceutical company Astellas China general manager Zhuo Yongqing said in Beijing, with the health insurance coverage of the population continues to expand, the future of China's pharmaceutical market will have a great development, Astellas will continue to increase investment in China, never give up any opportunity, the next five years will be the introduction of at least five new drug varieties to the Chinese market. On April 1 this year, Zhuo Yongqing assumed the post of General Manager of Astellas (China) Co., Ltd. and Vice Chairman of the China Association of Pharmaceuticals with Foreign Investment (CAFPI). A few days ago, Astellas Pharma China held a media conference in Beijing. Talking about whether it will consider acquiring Chinese companies, Zhuo Yongqing said the merger and acquisition of Chinese companies will be a very long process, need to do detailed market research, Astellas "will never give up any opportunity", but will be very cautious and careful to implement mergers and acquisitions in this matter.
Last year's sales in China amounted to about 750 million yuan
Back in 2005, Yamanouchi and Fujisawa merged to form Astellas Pharma, with 50 percent of each company's shares. In 2008, Astellas' sales in China amounted to about 750 million yuan, according to Zhuo Yongqing. Zhuo Yongqing said that after the merger of the two drug companies, Astellas Pharma each year growth of more than 20%, the entire Asian subsidiary's sales share of the world's 3% in the first half of this year accounted for about 45% -47% of Asia, equivalent to Astellas business in China accounted for more than 1% of the global business.
Compared with European and American pharmaceutical giants, Japanese pharmaceutical companies, including Astellas, started relatively late, and have a limited share of the global pharmaceutical field. In response to questions from Tencent Finance, Zhuo Yongqing said that in the late 1980s of the last century, Japanese pharmaceutical companies only really have some products in the U.S. market to occupy a certain share, which determines the current position of Japanese pharmaceutical companies in the world. Zhuo Yongqing that, at present, Astellas in the organ transplantation drugs and cephalosporin antibiotics in two areas has been a global leader, the Japanese pharmaceutical companies must seek breakthroughs in new drug development and global marketing network at two points, in order to occupy a place in the global pharmaceutical industry.
New health care reform brings huge business opportunities
Talking about the impact of the financial crisis on Astellas' business, Zhuo Yongqing believes that the crisis has had a very small impact on Astellas' growth because all of its subsidiaries are growing very well in local currency. "Specifically you can say there is no impact, but there is an impact on the financial statements." According to Zhuo Yongqing, because Astellas is a company listed in Japan, the currency used for financial statements is the yen, "when the dollar depreciates, it's beautiful to do locally, but it's not beautiful to do globally." Zhuo Yongqing believes that the financial crisis has almost no impact on Astellas' business in China, but instead the creation of healthcare reforms over the past two years has brought opportunities in the market. "Within the past six months, I've talked to many deans and many doctors, and they say that more and more patients are now being hospitalized, which shows that the Chinese pharmaceutical market is still growing." Zhuo Yongqing said Astellas last year, there are some varieties of sales growth of 20-30 percent, a few varieties of growth rate of more than 60 percent, of course, there are also some varieties is more unsatisfactory, may be the biggest impact of health care drugs.
Japanese firms cultivate generalist leaders
Since 1976, when he joined Fujisawa Pharmaceuticals' Taiwan office, Zhuo Yongqing has served Fujisawa Pharmaceuticals (including the merged Astellas) for 33 years. "I also think I'm an oddball; I started as a pharmaceutical representative, took care of the clinic market in Taiwan at first, and then went on to run big hospitals like Chang Gung Hospital." Zhuo Yongqing said he worked as a drug registrar, pharmaceutical representative, and planning manager. Later, he also did OTC sales, filmed TV commercials, and did almost all the jobs throughout the process, as well as acting as an agent for other multinational drug companies in Taiwan's marketing.
Zhuo Yongqing said, in the hiring mechanism, Europe and the United States pharmaceutical companies and Japanese pharmaceutical companies have a basic difference, is that the Japanese enterprises are training generalists, while the European and American pharmaceutical companies are specialized training. "European and American companies need you to have a professional job description in order to be appointed to the appropriate position, and has been in that position." Zhuo Yongqing said, Japanese companies will not say that there is only one function, such as the personnel department is short of people, "you are a sales manager, it is possible to pull you to the personnel department, Japanese companies to train a generalist, he will let you jump around," compared with European and American companies have their own advantages and disadvantages. Significance of existence
Contribute to the health of the world's people through the provision of innovative and reliable pharmaceutical products to a kind of efforts beyond others to continue to explore and discover the potential of life sciences, to meet the challenges, research and development of innovative medicines; through the provision of quality and reliable products as well as scientific and rigorous medical information, to win a high degree of customer trust; for the world's people's health to help life, to become a shining star in the global pharmaceutical industry. We will become a shining star in the global pharmaceutical industry.
Mission
Continuous enhancement of corporate value
Anstellas pursues continuous enhancement of corporate value.
Anstellas strives to become a company that is chosen and trusted by its stakeholders, thereby increasing its own corporate value. Our stakeholders include customers, shareholders, employees, and the global community.
Creed
The Creed provides a code of conduct that we are proud to live by on a daily basis, and Astellas has always used the Creed as a guide for our actions.
High ethical valuesAt all times, Astellas conducts its business activities with a high level of moral and ethical values.
Customer First: Always grasp the needs of our customers and take satisfaction of their needs as a guideline for our actions.
We will not be satisfied with the status quo, but we will challenge ourselves to innovate and create new values with a high level of ambition.
Competitive point of view to expand the vision, look outside, and create new value before rivals. Astellas Pharma Group was ranked 35th on Newsweek's 2008 Fortune 500 list, the highest among all Japanese companies, and eighth among global pharmaceutical companies. The Fortune 500 list was published in the July 9, 2008 issue of the Japanese-language edition of Newsweek, and the 2008 Newsweek Fortune 500 list identifies the world's top 500 companies based on a combination of financial performance and corporate social responsibility (CSR) among the top 1,000 companies in terms of 2006 sales. The financial performance score of the enterprise integrates three aspects: profitability, growth and security: profitability reflects the enterprise's operating profit margin on assets (operating profit/total assets) and operating profit margin on sales (operating profit/sales); growth combines the average annual growth rate of the enterprise's sales and annual cash flow statement; security focuses on evaluating the enterprise's interest affordability ratio [(pre-tax profit + interest paid) / interest paid]. / interest paid]. Astellas Pharma Group ranked first among pharmaceutical companies in terms of financial performance with an overall score of 56, with growth and safety receiving a perfect score of 20.
Corporate Social Responsibility (CSR) is evaluated in four areas: corporate management, employee development, social contribution, and environmental protection, with the relevant data coming from EIRIS (Ethical Investment Research services), a professional research company in the UK.
The Astellas Pharma Group, a young company established on April 1, 2005 through the merger of Yamanouchi Pharma and Fujisawa Pharmaceutical Industries, has been committed to researching and developing innovative and reliable pharmaceutical products that contribute to the health of people around the world, and to realizing our mission by continually improving our corporate value. In "Corporate Vision 2015," Astellas' future direction is clearly defined as concentrating its strengths and resources on research and development in therapeutic areas that require a high degree of specialization and for which there are currently no effective treatments, and to become even more competitive by providing high-value-added products globally. to highlight higher competitiveness and become a global leader in specialized therapeutic areas. The six focus areas are organ transplantation immunosuppression/inflammation, urology, infectious diseases, central nervous system/pain, diabetes and oncology.
Now Astellas Pharma Group implements a corporate social responsibility-based management system (CSR-based management), which means that we must not only achieve acceptance by our customers in our global market activities, but also achieve recognition and acceptance of respect in various aspects of operational, social and human caring, and become an important member of society's activities. October 1994 Shenyang Yamanouchi Pharmaceutical Company was established
March 1997 Shenyang Development Zone Plant was put into operation
December 1997 GMP certification of pharmaceutical products in China was obtained
November 1998 ISO-9002 environmental quality system certification was obtained
June 2001 Shenyang Yamanouchi Pharmaceutical Company was changed into Ltd. to a wholly owned enterprise
October 2001 ISO-14001 environmental quality system certification was obtained
May 2002 Formal name change to Yamanouchi Pharmaceutical (China) Co.Ltd.
February 2003 High-tech enterprise certification was obtained, and ISO-9001-2000 version certification was obtained
August 2005 Name change to Astellas Pharma (China) Ltd. Ltd.
March 2006 Integration of ISO-14000 and ISO-9000
April 2007 Merger with Fujisawa Pharmaceuticals (China) Ltd. Astellas Pharma Products: Transplantation Infections Procortisone; (Tacrolimus) Mecamylamine; (Meclofenac Sodium) Urodermatitis Urologic dermatologica Wisecom; (Solinacin) HAL; (tamsulosin hydrochloride) Puterpi; (tacrolimus) Digestive Circulation Dana; (beclomethasone sodium) Gosuda; (famotidine) Pell; (nicardipine hydrochloride)